Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aspnes

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
The Journal of Biological Chemistry|February 27, 2009
Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor designSeungil Han, Anil Mistry, Jeanne S Chang, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2011
Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine coreRobert L Dow, Melissa Andrews, Gary E Aspnes, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2023
6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptorGary E Aspnes, Scott W Bagley, Steven B Coffey, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2014
Identification of a novel conformationally constrained glucagon receptor antagonistEsther C Y Lee, Meihua Tu, Benjamin D Stevens, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2023
Small molecule inhibitors of PCSK9. SAR investigations of head and amine groupsGary E Aspnes, Steven B Coffey, Etzer Darout, et al.
Journal of Medicinal Chemistry|February 2, 2023
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open ScienceSven Thamm, Marina K Willwacher, Gary E Aspnes, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2013
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitusAngel Guzman-Perez, Jeffrey A Pfefferkorn, Esther C Y Lee, et al.
Journal of Medicinal Chemistry|June 8, 2018
Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic AgentsAllyn T Londregan, Liuqing Wei, Jun Xiao, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2013
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motifKevin J Filipski, Angel Guzman-Perez, Jianwei Bian, et al.
Journal of Medicinal Chemistry|January 7, 2016
Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) FamilyKim Huard, James R Gosset, Justin I Montgomery, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
The Journal of Biological Chemistry|February 27, 2009
Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor designSeungil Han, Anil Mistry, Jeanne S Chang, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2011
Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine coreRobert L Dow, Melissa Andrews, Gary E Aspnes, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2023
6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptorGary E Aspnes, Scott W Bagley, Steven B Coffey, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2014
Identification of a novel conformationally constrained glucagon receptor antagonistEsther C Y Lee, Meihua Tu, Benjamin D Stevens, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2023
Small molecule inhibitors of PCSK9. SAR investigations of head and amine groupsGary E Aspnes, Steven B Coffey, Etzer Darout, et al.
Journal of Medicinal Chemistry|February 2, 2023
Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open ScienceSven Thamm, Marina K Willwacher, Gary E Aspnes, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2013
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitusAngel Guzman-Perez, Jeffrey A Pfefferkorn, Esther C Y Lee, et al.
Journal of Medicinal Chemistry|June 8, 2018
Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic AgentsAllyn T Londregan, Liuqing Wei, Jun Xiao, et al.
Bioorganic & Medicinal Chemistry Letters|July 9, 2013
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motifKevin J Filipski, Angel Guzman-Perez, Jianwei Bian, et al.
Journal of Medicinal Chemistry|January 7, 2016
Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) FamilyKim Huard, James R Gosset, Justin I Montgomery, et al.
Pageof 9